Research programme: protein-based therapies - Alpine Immune Sciences/Horizon Therapeutics
Latest Information Update: 06 Nov 2023
At a glance
- Originator Alpine Immune Sciences
- Class Anti-inflammatories; Proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Autoimmune disorders
- Research Inflammation
Most Recent Events
- 17 Jan 2022 Preclinical trials in Autoimmune disorders in USA (Parenteral) as of January 2022 (Horizon Therapeutics pipeline, January 2022)
- 17 Dec 2021 Alpine Immune Sciences and Horizon Therapeutics plc agree to promote and co-develop protein-based therapeutics for autoimmune diseases and inflammatory diseases
- 17 Dec 2021 Early research in Autoimmune disorders in USA